SNIPR BIOME

Executive Summary

SNIPR BIOME is a Danish biotechnology company pioneering CRISPR-based precision medicines to combat antibiotic-resistant bacteria. Founded in 2017, the company leverages engineered bacteriophages and probiotics to deliver CRISPR-Cas systems that precisely target and eliminate resistant pathogens. Positioned as 'the CRISPR Microbiome Company,' SNIPR BIOME aims to address the global antimicrobial resistance crisis by developing targeted therapies that avoid the collateral damage of broad-spectrum antibiotics. Its platform combines synthetic biology, phage engineering, and CRISPR to create programmable living therapeutics that can selectively kill specific bacterial strains while preserving the beneficial microbiome. The company has advanced its lead candidate into Phase 2 clinical trials, demonstrating promising safety and efficacy in early studies. With antibiotic resistance on the rise, SNIPR BIOME's approach offers a novel solution for difficult-to-treat infections. The company is actively enrolling patients and has garnered interest from strategic partners. Successful Phase 2 data would be a major validation of the platform and could position SNIPR BIOME for a pivotal Phase 3 program. As a private company, it relies on venture funding and potential collaborations to advance its pipeline.

Upcoming Catalysts (preview)

• H2 2026Phase 2 clinical data readout for lead candidate45% success
• 2026Partnership or licensing deal with major pharma60% success
• Q4 2026Regulatory designation (e.g., Fast Track or QIDP) for lead program70% success